

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Austar Lifesciences Limited
奥星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6118)

POSITIVE PROFIT ALERT

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 and the information currently available to the Board, it is expected that a profit attributable to owners of the Company of not less than RMB30 million for the year ended 31 December 2025 will be recorded, as compared with a profit attributable to owners of the Company of approximately RMB16 million for the year ended 31 December 2024.

Such substantial profit growth primarily stems from (i) a decrease in operating expenses resulting from our deliberate focus on strategic efficiency enhancement, specifically, optimized administrative and research and development (“**R&D**”) expenditures; (ii) an increase in other gains which mainly derived from the exchange gains recorded for the year ended 31 December 2025; and (iii) a decrease in finance costs.

The optimization of the administrative and R&D expenditures is driven by the Group’s proactive initiatives in organizational streamlining and operational excellence, which reflect a more disciplined allocation of resources and our enhanced financial flexibility, helping the Group redirect resources toward strategic growth areas. These initiatives underscore not just short-term profitability, but a sustainable model for long-term value creation.

The Group is still in the process of finalising the annual results of the Group for the year ended 31 December 2025. The information contained in this announcement is only based on the preliminary assessment by the management of the Company by information currently available to the Group, including the unaudited consolidated management accounts of the Group for the year ended 31 December 2025, which has not been reviewed by the Company's auditors or the audit committee of the Board and may be subject to adjustments. Details of the Group's financial information and performance will be disclosed when the Group's annual results for the year ended 31 December 2025 are announced, which is expected to be published in late March 2026.

Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 6 February 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Madam Zhou Ning and Mr. Bian Ce; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.